Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com

Arbutus Biopharma (NASDAQ:ABUS) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Several other brokerages have also issued reports on ABUS. Chardan Capital reiterated a “buy” rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. JMP Securities lifted their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Trading Down 0.9 %

Shares of NASDAQ ABUS opened at $3.39 on Wednesday. Arbutus Biopharma has a one year low of $2.30 and a one year high of $4.73. The firm has a market capitalization of $642.38 million, a PE ratio of -7.88 and a beta of 1.93. The business has a 50-day moving average price of $3.33 and a two-hundred day moving average price of $3.65.

Institutional Trading of Arbutus Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. E Fund Management Co. Ltd. acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $34,000. Xponance Inc. acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $34,000. Raymond James Financial Inc. acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $34,000. Cibc World Markets Corp acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $45,000. Finally, Hsbc Holdings PLC acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $55,000. 43.79% of the stock is currently owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.